For the Inventor, By the Inventor

Enter assignee name

Carmiel, Israel

Protalix Ltd.

USPTO Granted Patents = 27

% Expired Patents = 29.6

CIPO Patents = 2

EPO Patents = 20

Trademarks = 1

Forward Citations = 100

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Yoseph Shaaltiel (23 out of 23 patents)

Avidor Shulman (11 out of 18 patents)

Tali Kizhner (11 out of 11 patents)

4. Ilya Ruderfer (10 out of 10 patents)

5. Uri Hanania (9 out of 9 patents)

6. Gideon Baum (8 out of 12 patents)

7. Sharon Hashmueli (7 out of 7 patents)

8. Daniel Bartfeld (7 out of 7 patents)

9. Ayala Lewkowicz (6 out of 8 patents)

10. Talia Shekhter (5 out of 5 patents)

11. Yaniv Azulay (5 out of 5 patents)

12. Liat Fux (4 out of 4 patents)

13. Tehila Ben-Moshe (4 out of 9 patents)

14. Svetlana Gingis-Velitski (3 out of 3 patents)

15. Tami Ariel (3 out of 3 patents)

27 patents: Sort by Forward Citations

1. 12703857 - METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACID (2026-08-11),

2. 12674146 - MODIFIED URICASE AND USES THEREOF (2026-07-07),

3. 12385054 - Removal of constructs from transformed cells (2025-08-12),

4. 12385026 - Stabilized alpha-galactosidase and uses thereof (2025-08-12),

5. 12194079 - Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase (2025-01-14),

6. 11814657 - Modified DNase and uses thereof (2023-11-14),

7. 11225648 - Modified DNase and uses thereof (2022-01-18),

8. 10870842 - Stabilized alpha-galactosidase and uses thereof (2020-12-22),

9. 10730925 - Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same (2020-08-04),

10. 10364413 - Large scale disposable bioreactor (2019-07-30),

11. 10280414 - Stabilized α-galactosidase and uses thereof (2019-05-07),

12. 10087232 - Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy (2018-10-02),

13. 10000551 - Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same (2018-06-19),

14. 9732333 - Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells (2017-08-15),

15. 9708595 - Stabilized alpha-galactosidase and uses thereof (2017-07-18),

Protalix Ltd. is a biopharmaceutical company based in Carmiel, Israel, specializing in the development and commercialization of innovative therapies derived from its proprietary plant cell-based protein expression system. The company focuses on producing therapeutic proteins for various medical conditions, including rare diseases. Protalix aims to address unmet medical needs through its advanced biotechnological approaches, leveraging its expertise in protein production and formulation to enhance patient outcomes globally.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

27 Patents

#1 in Carmiel

#223 in Israel

#23,968 in the World

Carmiel, Israel

Protalix Ltd.

Forward Citations = 100

46 inventors:

Yoseph Shaaltiel (23 out of 23 patents)

Avidor Shulman (11 out of 18 patents)

Tali Kizhner (11 out of 11 patents)

4. Ilya Ruderfer (10 out of 10 patents)

5. Uri Hanania (9 out of 9 patents)

Please report any incorrect information to [email protected]

Loading…